OMNI 360 Wealth Inc. Acquires 753 Shares of Pfizer Inc. (NYSE:PFE)

OMNI 360 Wealth Inc. boosted its position in Pfizer Inc. (NYSE:PFE) by 7.4% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 10,979 shares of the biopharmaceutical company’s stock after purchasing an additional 753 shares during the period. OMNI 360 Wealth Inc.’s holdings in Pfizer were worth $278,000 as of its most recent SEC filing.

Other institutional investors have also bought and sold shares of the company. Rialto Wealth Management LLC purchased a new stake in shares of Pfizer during the fourth quarter worth $26,000. Clarity Asset Management Inc. bought a new position in Pfizer in the fourth quarter valued at $27,000. Gould Capital LLC increased its stake in Pfizer by 97.2% in the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 493 shares during the last quarter. North Capital Inc. purchased a new stake in Pfizer during the first quarter valued at about $28,000. Finally, Bernard Wealth Management Corp. purchased a new stake in Pfizer during the fourth quarter valued at about $30,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Stock Up 1.1%

Pfizer stock opened at $25.52 on Tuesday. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $31.54. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.96 and a current ratio of 1.26. The firm has a 50 day moving average price of $23.76 and a 200 day moving average price of $24.81. The company has a market capitalization of $145.11 billion, a PE ratio of 18.52, a price-to-earnings-growth ratio of 0.92 and a beta of 0.58.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, topping analysts’ consensus estimates of $0.67 by $0.25. The firm had revenue of $13.72 billion during the quarter, compared to the consensus estimate of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. The company’s revenue was down 7.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.82 earnings per share. Research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.74%. Pfizer’s payout ratio is 124.64%.

Analyst Ratings Changes

A number of analysts have recently weighed in on the stock. Hsbc Global Res upgraded shares of Pfizer to a “strong-buy” rating in a report on Monday, March 10th. BMO Capital Markets decreased their target price on shares of Pfizer from $36.00 to $30.00 in a research note on Thursday, April 17th. Wolfe Research raised their price target on shares of Pfizer from $22.00 to $23.00 and gave the company an “underperform” rating in a research report on Wednesday, April 30th. Leerink Partners reduced their price target on shares of Pfizer from $28.00 to $26.00 and set a “market perform” rating for the company in a research report on Wednesday, April 30th. Finally, Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a research report on Tuesday, March 18th. One analyst has rated the stock with a sell rating, thirteen have issued a hold rating, six have assigned a buy rating and three have given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $28.55.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.